McDonnell Michael R. 4

What Happened Michael R. McDonnell, a director of Moderna, received derivative awards on July 8, 2026 totaling 14,766 shares. The Form 4 lists three grants/awards: 7,415 shares, 1,618 shares and 5,733 shares, each reported at $0.00 per share (awarded/issued rather than bought or sold). These are compensation-related awards (stock option and restricted stock units) rather than open-market purchases or sales.

Key Details

• Transaction date: July 8, 2026; Form filed July 10, 2026 (appears timely — within two business days).
• Grants reported: 7,415 shares @ $0.00; 1,618 shares @ $0.00; 5,733 shares @ $0.00 — total 14,766 derivative shares.
• Shares owned after transaction: Not disclosed in the information provided.
• Footnotes from the filing:
  • F1: An option will become fully vested and exercisable on July 8, 2027.
  • F2: Restricted stock units convert into common stock on a one-for-one basis.
  • F3: One RSU award vests in full on July 8, 2027.
  • F4: One RSU award vests in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting, subject to continued service.

Context These are grant/award transactions (Form 4 code "A") — effectively compensation that creates potential future ownership once vesting conditions are met. They do not represent an immediate cash purchase or sale of shares. Monitor future filings for vesting, exercises, or any subsequent open-market sales that would convert these derivative awards into tradable shares.